Literature DB >> 2682408

Two substrates for medial forebrain bundle self-stimulation: myelinated axons and dopamine axons.

J S Yeomans1.   

Abstract

The directly activated substrates for medial forebrain bundle (MFB) self-stimulation are primarily low threshold, myelinated axons with absolute refractory periods of 0.4 to 1.2 msec, conduction velocities of 1 to 8 m/sec and current-distance constants of 1000 to 3000 microA/mm2. When small electrode tips or high currents are used, however, a second population of long refractory period (1.2 to 5 msec) axons is added. The excitability properties of this second population are almost identical with those of dopamine (DA) axons. Furthermore, the long-refractory period effects of MFB self-stimulation are reduced, but not completely blocked, by peripheral injections of alpha-flupenthixol, suggesting that dopamine axons make small contributions to MFB self-stimulation when small tips are used. Collision data, strength-duration data and refractory period data in various self-stimulation experiments are compared. Asymmetric collision effects, recently observed in cortical and striatal sites mediating electrically evoked turning, may help determine where synapses are located in circuits mediating electrically evoked behaviors. A neural model of symmetric, asymmetric and mixed collision is proposed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682408     DOI: 10.1016/s0149-7634(89)80016-8

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  16 in total

Review 1.  Motivational Processes Underlying Substance Abuse Disorder.

Authors:  Paul J Meyer; Christopher P King; Carrie R Ferrario
Journal:  Curr Top Behav Neurosci       Date:  2016

2.  Disruption of dopamine neuron activity pattern regulation through selective expression of a human KCNN3 mutation.

Authors:  Marta E Soden; Graham L Jones; Christina A Sanford; Amanda S Chung; Ali D Güler; Charles Chavkin; Rafael Luján; Larry S Zweifel
Journal:  Neuron       Date:  2013-10-24       Impact factor: 17.173

3.  Brain reinforcement system function is ghrelin dependent: studies in the rat using pharmacological fMRI and intracranial self-stimulation.

Authors:  Paul J Wellman; P Shane Clifford; Juan A Rodriguez; Samuel Hughes; Carla Di Francesco; Sergio Melotto; Michela Tessari; Mauro Corsi; Angelo Bifone; Alessandro Gozzi
Journal:  Addict Biol       Date:  2011-10-21       Impact factor: 4.280

Review 4.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

5.  Catecholaminergic axons in the neocortex of adult mice regrow following brain injury.

Authors:  Sarah E Dougherty; Tymoteusz J Kajstura; Yunju Jin; Michelle H Chan-Cortés; Akhil Kota; David J Linden
Journal:  Exp Neurol       Date:  2019-11-04       Impact factor: 5.330

Review 6.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 7.  Drive and Reinforcement Circuitry in the Brain: Origins, Neurotransmitters, and Projection Fields.

Authors:  Roy A Wise; Ross A McDevitt
Journal:  Neuropsychopharmacology       Date:  2017-10-06       Impact factor: 7.853

Review 8.  Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory.

Authors:  Satoshi Ikemoto
Journal:  Neurosci Biobehav Rev       Date:  2010-02-10       Impact factor: 8.989

Review 9.  A selectionist approach to reinforcement.

Authors:  J W Donahoe; J E Burgos; D C Palmer
Journal:  J Exp Anal Behav       Date:  1993-07       Impact factor: 2.468

10.  Synaptic overflow of dopamine in the nucleus accumbens arises from neuronal activity in the ventral tegmental area.

Authors:  Leslie A Sombers; Manna Beyene; Regina M Carelli; R Mark Wightman
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.